ESM-1在复发性垂体腺瘤中的表达及意义

doi:10.3969/j.issn.1009-976X.2022.01.017

岭南现代临床外科 ›› 2022, Vol. 22 ›› Issue (01): 94-97.DOI: 10.3969/j.issn.1009-976X.2022.01.017

ESM-1在复发性垂体腺瘤中的表达及意义

赵昭¹, 阎晓玲^2,*

1.天津市环湖医院神经外科;
2.天津市环湖医院病理科,天津300350

通讯作者: *阎晓玲,Email：riokoss@hotmail.com

Expression and significance of immunehisto chemical levels of ESM-1 in recurrent pituitary adenoma

ZHAO Zhao¹, YAN Xiao-ling²

1. Department of Neuro surgery;
2. Department of Pathology,Tianjin Huanhu Hospital Tianjin 300350, China

Received:2021-09-26 Online:2022-03-17 Published:2022-03-17
Contact: YAN Xiao-ling, riokoss@hotmail.com

摘要/Abstract

摘要： 目的探讨ESM-1在免疫组化水平的表达与垂体腺瘤复发的相关性。方法对2018年2月至2021年4月就诊于我院的33例垂体腺瘤患者进行ESM-1抗体的免疫组化染色并进行分析研究。结果复发组相较首发组有更高的ESM-1表达（P=0.004）,而年龄、性别及肿瘤最大径均与ESM-1表达无明显相关性,患者复发前后的ESM-1表达无明显差异,ki-67蛋白阳性表达指数与ESM-1表达之间无明显相关性。结论 ESM-1的表达与肿瘤复发有明显相关性,对于垂体腺瘤的治疗及预后有指导作用。

关键词: 垂体腺瘤, 免疫组化, ESM-1

Abstract: Objective To explore the correlation of ESM-1 expression at the immunohistochemical level and the recurrence of pituitary adenoma. Methods Immunohistochemical staining of ESM-1 antibody was performed on 33 pituitary adenoma patients attending our hospital from February 2018 to April 2021. Results The relapse group had higher ESM-1 expression （P=0.004）, while age, sex and tumor maximum diameter had no significant correlation with ESM-1 expression, no significant difference in ESM-1 expression before and after relapse, and no obvious correlation between ki-67-positive protein expression index and ESM-1 expression. Conclusions The expression of ESM-1 is clearly correlated with tumor recurrence, and it guides the treatment and prognosis of pituitary adenoma.

Key words: pituitary adenoma, immunohistochemistry, ESM-1

中图分类号:

R739.41

赵昭, 阎晓玲. ESM-1在复发性垂体腺瘤中的表达及意义[J]. 岭南现代临床外科, 2022, 22(01): 94-97.

ZHAO Zhao, YAN Xiao-ling. Expression and significance of immunehisto chemical levels of ESM-1 in recurrent pituitary adenoma[J]. Lingnan Modern Clinics In Surgery, 2022, 22(01): 94-97.

参考文献

[1] Molitch ME.Diagnosis and Treatment of Pituitary Adenomas: A Review[J]. JAMA, 2017, 317(5):516-524.
[2] Cho HJ, Kim H, Kwak YJ,et al.Clinicopathologic analysis of pituitary adenoma: a single institute experience[J]. J Korean Med Sci, 2014, 29(3):405-410.
[3] Bodhinayake I, Ottenhausen M, Mooney MA,et al.Results and risk factors for recurrence following endoscopic endonasal transsphenoidal surgery for pituitary adenoma[J]. Clin Neurol Neurosurg, 2014, 119:75-79.
[4] Li C, Geng H, Ji L, et al.ESM-1: A Novel Tumor Biomaker and its Research Advances[J]. Anticancer Agents Med Chem, 2019, 19(14):1687-1694.
[5] Grigoriu BD, Depontieu F, Scherpereel A, et al.Endocan expression and relationship with survival in human non-small cell lung cancer[J]. Clin Cancer Res, 2006, 12(15):4575-4582.
[6] Leroy X, Aubert S, Zini L, et al.Vascular endocan (ESM-1) is markedly overexpressed in clear cell renal cell carcinoma[J]. Histopathology, 2010, 56(2):180-187.
[7] Kang YH, Ji NY, Han SR, et al.ESM-1 regulates cell growth and metastatic process through activation of NF-κB in colorectal cancer[J]. Cell Signal, 2012, 24(10):1940-1949.
[8] Hatfield KJ, Lassalle P, Leiva RA, et al.Serum levels of endothelium-derived endocan are increased in patients with untreated acute myeloid leukemia[J]. Hematology, 2011, 16(6):351-356.
[9] Sagara A, Igarashi K, Otsuka M, et al.Endocan as a prognostic biomarker of triple-negative breast cancer[J]. Breast Cancer Res Treat, 2017, 161(2):269-278.
[10] Maurage CA, Adam E, Minéo JF, et al.Endocan expression and localization in human glioblastomas[J]. J Neuropathol Exp Neurol, 2009, 68(6):633-641.
[11] Miao Y, Zong M, Jiang T, et al.A comparative analysis of ESM-1 and vascular endothelial cell marker (CD34/CD105) expression on pituitary adenoma invasion[J]. Pituitary, 2016, 19(2):194-201.
[12] Wang S, Wu Z, Wei L, Zhang J.Endothelial cell-specific molecule-1 as an invasiveness marker for pituitary null cell adenoma[J]. BMC Endocr Disord, 2019, 19(1):90.
[13] Batista RL, Trarbach EB, Marques MD, et al.Nonfunctioning pituitary adenoma recurrence and its relationship with sex, size, and hormonal immunohistochemical profile[J]. World Neurosurg, 2018, 120:e241-e246.
[14] Grigsby PW,Simpson JR,Fineberg B.Late regrowth of pituitary adenomas after irradiation and/or surgery. Hazard function analysis[J]. Cancer, 1989, 63(7):1308-1312.
[15] Béchard D,Gentina T,Delehedde M,et al.Endocan is a novel chondroitin sulfate/dermatan sulfate proteoglycan that promotes hepatocyte growth factor/scatter factor mitogenic activity[J]. J Biol Chem, 2001, 276(51):48341-48349.
[16] van′t Veer LJ, Dai H, van de Vijver MJ,et al. Gene expression profiling predicts clinical outcome of breast cancer[J]. Nature, 2002, 415(6871):530-536.
[17] Jin H, Rugira T, Ko YS, et al.ESM-1 Overexpression is involved in increased tumorigenesis of radiotherapy-resistant breast cancer cells[J]. Cancers (Basel), 2020, 12(6):1363.
[18] Balta S, Balta I, Mikhailidis DP.Endocan: a new marker of endothelial function[J]. Curr Opin Cardiol, 2021, 36(4):462-468.

ESM-1在复发性垂体腺瘤中的表达及意义

Expression and significance of immunehisto chemical levels of ESM-1 in recurrent pituitary adenoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 8

编辑推荐

Metrics

[1]	冯子泽, 伍益, 李智斌, 董家军, 古机泳, 彭逸龙. 替莫唑胺治疗难治性垂体腺瘤[J]. 岭南现代临床外科, 2020, 20(04): 527-530.
[2]	高晓琳, 修霞, 邱萍萍, 张杜合一, 谢舒乐, 林钊宇. FOS样抗原1在头颈鳞癌中的表达及临床意义[J]. 岭南现代临床外科, 2020, 20(03): 319-323.
[3]	陈景森，欧希，赵洋，余光银，刘晓平*. LAP+CD4+T细胞在肝癌微环境中的分布特点及意义[J]. 岭南现代临床外科, 2019, 19(05): 528-532.
[4]	梁家宏，许侨东，严江*. 结直肠癌中FAM135B 基因的表达及功能的生物信息学分析[J]. 岭南现代临床外科, 2018, 18(03): 265-268.
[5]	陈景林黄炎松曾今诚蔡海鹏. 抑癌基因PTEN与Beclin1在膀胱癌中的表达及临床意义[J]. 岭南现代临床外科, 2016, 16(02): 219-222.
[6]	柳叶青李海凤韩静静黄志权李海刚. GPX1和SOD1在腺样囊性癌中的表达及其意义[J]. 岭南现代临床外科, 2013, 13(06): 537-540.
[7]	叶国华韦金星. Vps4在肝癌及癌旁组织中的差异性表达及其临床意义[J]. 岭南现代临床外科, 2013, 13(02): 87-90.
[8]	张广献杨海峰曾宪成*. 白细胞抗原G在结肠癌中的表达及意义[J]. 岭南现代临床外科, 2013, 13(02): 99-102.